Regulators at the Shenzhen Stock Exchange have released four illustrative case studies focusing on typical accounting and auditing challenges, offering practical clarity for professionals navigating complex financial reporting scenarios. These cases address auditing procedures for internal controls as well as critical accounting treatments related to research and development expenditures, intangible assets, and share-based payments.
Audit Procedure Question One: Collecting Evidence on Internal Control Effectiveness
Auditor A, while reviewing the sales and receivables cycle at H, a listed company, singled out two key controls: the multi-departmental review of customer orders and the requirement for functional leaders to sign off on order review forms. Despite this identification, the auditor did not obtain the actual review documents during the control testing phase and consequently failed to verify how these specific controls were operating. According to CSA 1231, auditors are required to gather sufficient appropriate evidence that controls are functioning as designed. In this instance, Auditor A should have retrieved the signed order review forms as part of the sample testing to confirm the effectiveness of these specific control activities.
Audit Procedure Question Two: Responding to Deviations Discovered in Control Testing
During a test of the purchase-to-pay cycle at M, a listed company, Auditor B examined the control point related to proper approval and execution of purchase contracts. A sample contract contained an obvious anomaly: its stated term ran until the end of 20X2, yet the official seal application was dated well after that, in September of 20X3. The auditor recorded this as "effective" in the work papers without performing any additional audit steps. CSA 1231 states that when a deviation is found in a control the auditor intends to rely upon, the auditor must make specific inquiries to understand the deviation, its potential consequences, and whether further procedures are warranted. Auditor B was obligated to investigate the cause and likely impact of this timing discrepancy and then evaluate the need for further audit work.
Audit Procedure Question Three: Adhering to Planned Sample Sizes in Control Testing
In testing N, a listed company's sales cycle controls, Auditor C had predetermined a sample size of 25 items based on the control frequency. However, only 12 items were actually tested, with no documentation explaining the shortfall or any subsequent audit procedures. Under the auditing standard on sampling, if an auditor cannot perform the planned procedures on a selected item or a substitute, the item should be treated as a deviation in the control testing. In this situation, Auditor C needed to test 13 more items, or if that proved impossible, treat the shortfall as a control deviation and perform further procedures to understand its implications.
Summary on Control Testing
Effective control testing is a critical component of an audit, as it directly influences the nature and extent of substantive procedures. If auditors are unable to gather appropriate evidence about control effectiveness and do not address deviations, they may fail to identify material misstatements in the financial statements. Key takeaways for auditors include carefully considering the level of reliance on controls, the frequency and duration of the controls, and the expected deviation rate when scoping their testing. When executing tests, auditors must gather the necessary evidence to support their conclusions and properly document results. If sampling reveals deviations, whether they indicate a systemic issue or potential fraud, auditors must take targeted action and consider the impact on the overall audit strategy.
Case One: Accounting for the Acquisition of a Company's In-Progress Research Project
A, a pharmaceutical company, entered an agreement granting it exclusive, non-transferable rights to develop a drug candidate, which was still in Phase II trials. A was fully responsible for all future development costs and would jointly share commercial benefits after a successful launch. The purchase price included a fixed license fee of 15 million yuan. The company initially recognized the acquired in-process research as an intangible asset and began amortizing it. The core question is whether this treatment is appropriate. The guidance suggests that the accounting for acquired research projects should align with the company's internal capitalization policy for development costs. Since the license is not transferable, it cannot generate economic benefits through resale. Therefore, unless the project has met the criteria for capitalization, the associated expenditure should be treated as a research and development expense in the period incurred, rather than being capitalized as an intangible asset.
Case Two: Determining the Amortization Start Date for Customized Software
B commissioned a vendor to customize software on its existing systems at a total cost of 20 million yuan, payable over five years. The contract specified a two-stage acceptance process: an initial test, followed by a trial operation period where users could identify issues. The final acceptance would only occur after these were resolved. Since the software was operational with core functions available, but some modules required further adjustment, the period between initial and final acceptance was substantial. The question is when amortization should begin. According to the accounting standard, amortization of an intangible asset should begin when it is available for use. Here, the company must assess whether the post-trial adjustments constitute significant modifications. If all key functions are essentially operational and final acceptance is a mere formality, the software is likely in a condition to be used and amortization should start. Conversely, if major functions are missing and require significant rework, the asset is not yet available for use and amortization should be deferred until that point.
Summary on R&D and Intangible Assets
With an increase in research-intensive companies, especially in emerging sectors, the treatment of R&D spending is under close scrutiny. Professional judgment is needed to prevent earnings management through aggressive capitalization of development costs or delaying the start of amortization. For acquired in-process technology, if it's for research or hasn't met capitalization criteria and can't be sold, the costs must be expensed. For customized software, availability for use should be determined by the functionality achieved, not solely on formal acceptance milestones.
Case Three: Assessing Share-Based Payment for an Employee Stock Plan in a Private Placement
Company C issued shares through a private placement to both an employee stock ownership plan (ESOP) and unrelated external investors. The issuance price met regulatory conditions. The arrangement was negotiated by all parties. If the ESOP subscribes for shares under terms and conditions that are no more favorable than those offered to external investors, the price can be considered to represent fair value. In that case, employees do not receive a benefit that would constitute compensation for their services, and the transaction would not be treated as share-based payment.
Case Four: Handling a Share Grant to an Associate's Executive by a Non-Controlling Shareholder
Company D held a 40% stake in an associate, Company J. According to an agreement, if J met certain performance targets, D and J's controlling shareholder would together award 12% of J's shares to J's general manager over three years. The key question is whether this grant constitutes share-based payment for both J and D. For J, which receives the services, it does constitute a share-based payment even though the grantor is not its controlling shareholder. As J has no obligation to settle, it must account for the awards as an equity-settled share-based payment, recognizing the remuneration expense and a corresponding entry to equity. For D, the shares it grants are not an equity instrument of the group, but rather an asset D holds. Since the services are provided to J, not D, the arrangement falls outside the scope of share-based payment and employee compensation standards for D. Instead, D accounts for its investment in J using the equity method, recognizing the share of J's expense as a reduction in the carrying amount of the investment and a corresponding debit to profit or loss, and likewise for the equity movements.
Summary on Share-Based Payments
The various forms of share-based payment arrangements require a careful analysis of the specific facts and circumstances. A crucial test is whether the purchase price or exercise price is at fair value. The accounting treatment for these arrangements also extends to different parties within a broader corporate structure. It is important to remember that a grantor of equity instruments does not have to be the controlling shareholder; any shareholder involved in a group transaction can trigger the share-based payment rules for the entity that receives the employee services.